z-logo
open-access-imgOpen Access
Variation in breast cancer grading in 1,636 resections assessed using control charts and in silico kappa
Author(s) -
Jinesa Moodley,
Phillip Williams,
Gabriela Gohla,
Pierre Major,
Michael Bonert
Publication year - 2020
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0242656
Subject(s) - kappa , breast cancer , medicine , grading (engineering) , nuclear medicine , cancer , mathematics , biology , ecology , geometry
Objective Assess interpretative variation in Nottingham grading using control charts (CCs) and in silico kappa (ISK). Methods In house invasive breast cancer cases (2011–2019) at two institutions with a synoptic report were extracted. Pathologist interpretative rates (PIRs) were calculated and normed for Nottingham grade (G) and its components (tubular score (TS), nuclear score (NS), mitotic score (MS)) for pathologists interpreting >35 cases. ISKs were calculated using the ordered mutually exclusive category assumption (OMECA) and maximal categorical overlap assumption (MCOA). Results The study period included 1,994 resections. Ten pathologists each assessed 38–441 cases and together saw 1,636; these were further analyzed. The PIR medians (normed ranges) were: G1:24%(18–27%), G2:53%(43–56%) and G3:26%(19–33%). The MCOA ISK and the number of statistical outliers (p< 0.05/p< 0.001) to the group median interpretive rate (GMIR) for the ten pathologists was G1: 0.82(2/0 of 10), G2: 0.76(1/1), G3: 0.71(3/1), TS1: 0.79(1/0), TS2: 0.63(5/1), TS3: 0.66(5/1), NS1: 0.37(5/4), NS2: 0.60(4/3), NS3: 0.59(4/4), MS1: 0.78(3/1), MS2: 0.78(3/1), MS3: 0.77(2/0). The OMECA ISK was 0.62, 0.49, 0.69 and 0.71 for TS, NS, MS and G. Conclusions The nuclear score has the most outliers. NS1 appears to be inconsistently used. ISK mirrors trends in conventional kappa studies. CCs and ISK allow insight into interpretive variation and may be essential for the next generation in quality.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here